L. brevis

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the provided abstracts, Levilactobacillus (Lactobacillus) brevis is most frequently studied in two applied domains: (1) food fermentation/food quality and (2) probiotic/host-interaction functions. In fermented vegetables, L. brevis appears both as a naturally occurring lactic acid bacterium in traditional products and as a defined starter culture to control fermentation. Starter-based work (e.g., radish paocai) emphasizes fermentation kinetics (rapid sugar utilization and acidification), product physicochemical traits (texture and color), and flavor chemistry (shifts in organic acids and aroma-active VOCs). In parallel, multiple studies focus on probiotic screening and mechanistic potential, including survival under simulated gastric conditions, adhesion to epithelial cells, antimicrobial activity against foodborne or oral pathogens, antioxidant capacity, and immunomodulatory readouts.

The strongest evidence in these abstracts supports L. brevis as a functional fermentation organism that can improve process control and sensory quality when used as a starter, with measurable increases in key metabolites (e.g., lactic/acetic acid, mannitol) and favorable modulation of volatile profiles linked to consumer acceptability. For probiotic-related outcomes, the evidence is strongest for in vitro and ex vivo properties: antimicrobial activity against pathogens, epithelial adhesion, and production of neuroactive compounds (notably GABA and acetylcholine) in batch culture and gut-simulator systems, alongside microbiota compositional shifts. Human evidence is emerging but limited: a randomized, double-blind, placebo-controlled cross-over trial of a two-strain formulation including L. brevis reported improvements in depressive symptom-related cognitive measures (e.g., rumination, cognitive reactivity) without changes in subjective stress, and did not establish clear links between fecal neurotransmitter levels and psychological outcomes.

Key gaps include the need for larger, longer, and more targeted clinical trials to determine whether L. brevis-containing interventions reproducibly improve mental health, stress-related outcomes, or cognition, and to clarify dose–response, responder phenotypes, and durability of effects. Mechanistically, further work is needed to connect strain-specific neuroactive production to host-relevant biomarkers (circulating metabolites, neural/immune signaling) rather than fecal measures alone, and to disentangle the contribution of L. brevis within multi-strain formulations. For food applications, broader validation across substrates, processing conditions, and safety/quality endpoints (including standardization of sensory markers and VOC signatures) would strengthen generalizability, while oral-health findings warrant controlled human studies to confirm anti-caries and immunomodulatory benefits and to assess ecological impacts on the oral microbiome.

1. What conditions has L. brevis been studied for?

  • Gut/intestinal inflammation and barrier dysfunction (IBD-relevant models): Studied in an in vitro co-culture model of intestinal epithelial cells (Caco-2) and macrophages (RAW264.7) under inflammatory stimulation (LPS), using live and pasteurized L. brevis IBRC‑M10790.

  • Mood-related outcomes in stressed adults (psychobiotic research): Studied as part of a two-strain probiotic formulation (Levilactobacillus brevis P30021 + Lactiplantibacillus plantarum P30025) in moderately stressed healthy adults, focusing on depressive symptoms–related cognitive patterns (e.g., rumination, cognitive reactivity to sad mood) and cognition testing.

  • Neuroactive compound production (mechanistic psychobiotic work): Evaluated in vitro (batch culture and SHIME® gut simulator) for production of GABA and acetylcholine (not a clinical condition per se, but relevant to stress/mood hypotheses).

  • Oral health (dental caries–related pathogen control and inflammation): An oral isolate (L. brevis BBE‑Y52) studied for antimicrobial activity against Streptococcus mutans, adherence to oral epithelial cells, and immune modulation (IL‑10/IL‑12p70 ratio in PBMCs).

  • Immune modulation/“immune-enhancing” activity: Heat-treated L. brevis KU15159 studied in macrophage cell experiments (RAW 264.7) for nitric oxide and cytokine responses and MAPK pathway activation.

  • Food safety/food fermentation contexts (not clinical treatment): Multiple abstracts describe L. brevis in vegetable/fruit fermentation and as a starter culture (e.g., radish paocai) affecting fermentation kinetics, metabolites, and sensory quality.

  • General probiotic screening (antimicrobial/antioxidant traits): L. brevis KU15153 (from kimchi) evaluated for simulated gastric survival, adhesion to HT‑29 cells, antimicrobial activity against food-borne pathogens, and antioxidant activity.

2. Does it work in treating those conditions? Summarize the evidence.

  • IBD / intestinal inflammation: Evidence is preclinical (in vitro). In the Caco-2/RAW264.7 co-culture model, live and pasteurized L. brevis IBRC‑M10790 decreased pro-inflammatory cytokines (IL‑6, IL‑1β, TNF‑α) and increased IL‑10, and also increased barrier-related markers (ZO‑1, E‑cadherin, occludin). Notably, pasteurized bacteria showed a higher protective effect than live bacteria in this model. This supports potential benefit, but it is not clinical proof of treatment efficacy.

  • Mood/stress-related outcomes: Evidence includes a 12-week randomized, double-blind, placebo-controlled cross-over human trial of a two-strain formulation (includes L. brevis P30021). The probiotic had no effect on subjective stress measures, but showed a significant benefit on depressive-symptom–related measures: reduced cognitive reactivity to sad mood (p=0.034) and improved rumination (p=0.006). Because the intervention was a combination product, the specific contribution of L. brevis alone cannot be isolated from this abstract.

  • Mechanistic support for psychobiotic claims: In vitro batch fermentation and SHIME® experiments showed the selected strains (including L. brevis P30021) could increase GABA and acetylcholine production and decrease glutamate in these systems; GABA production was confirmed in SHIME® short-term experiments. These findings support biological plausibility, but they do not demonstrate clinical treatment effects.

  • Oral health (caries-related): Evidence is laboratory and immune-cell based. L. brevis BBE‑Y52 inhibited S. mutans, produced antimicrobial compounds (hydrogen peroxide, lactic acid), adhered to oral epithelial cells, and shifted immune signaling toward a higher IL‑10-to-IL‑12p70 ratio in PBMC co-incubation (suggesting anti-inflammatory potential). This supports candidacy for oral care products, but not proven clinical prevention/treatment of caries in humans from these abstracts.

  • Immune “enhancement”: Heat-treated L. brevis KU15159 increased nitric oxide and phagocytic activity and upregulated iNOS and pro-inflammatory cytokines (TNF‑α, IL‑1β, IL‑6) via MAPK activation in macrophage experiments. This shows immune activation in vitro; whether that translates to clinical benefit depends on context and is not established here.

3. What health benefits does it have?

  • Potential anti-inflammatory and barrier-support effects in the gut (preclinical): In an IBD-relevant in vitro model, L. brevis IBRC‑M10790 reduced inflammatory cytokines (IL‑6, IL‑1β, TNF‑α), increased IL‑10, and increased tight/adherens junction markers (ZO‑1, occludin, E‑cadherin), suggesting improved epithelial barrier integrity.

  • Potential mood-related benefits (human evidence, combination product): In moderately stressed healthy adults, a probiotic containing L. brevis P30021 improved rumination and reduced cognitive reactivity to sad mood, outcomes relevant to depressive symptom patterns. No improvement in subjective stress was observed.

  • Neuroactive metabolite production (mechanistic): Selected L. brevis strains (notably P30021) were chosen for in vitro production of GABA and acetylcholine, and supplementation increased these neuroactive metabolites in in vitro gut models (batch culture; SHIME®), supporting a plausible gut–brain mechanism.

  • Antimicrobial activity against pathogens (strain-dependent): L. brevis KU15153 inhibited multiple food-borne pathogens (E. coli, Listeria monocytogenes, Salmonella Typhimurium, Staphylococcus aureus) in reported assays. L. brevis BBE‑Y52 inhibited S. mutans (caries-associated).

  • Antioxidant activity (strain-dependent, in vitro): L. brevis KU15153 showed higher antioxidant activity than L. rhamnosus GG in DPPH radical scavenging and β-carotene/linoleic acid inhibition assays.

  • Food fermentation benefits (not a direct human health outcome, but relevant to diet quality and safety): As a starter culture in radish paocai, L. brevis PL6‑1 accelerated acid production, increased mannitol and organic acids, improved texture and sensory acceptability, and shifted aroma compounds toward more desirable notes while reducing unpleasant sulfurous odors.

4. Does it have any downsides or side effects?

  • Human side effects are not reported in these abstracts: The 12-week human cross-over trial reports psychological outcomes but does not describe adverse events in the provided abstract text, so tolerability cannot be assessed from what is shown.

  • Immune activation could be a double-edged sword (preclinical): Heat-treated L. brevis KU15159 increased nitric oxide and pro-inflammatory cytokines (TNF‑α, IL‑1β, IL‑6) in macrophages. While framed as “immune-enhancing,” such activation could theoretically be undesirable in people with certain inflammatory conditions; however, this is speculative and not tested clinically in the abstracts.

  • Strain-specific safety varies and cannot be generalized: One strain (L. brevis KU15153) was described as non-hemolytic, antibiotic-susceptible, and not producing carcinogenic β-glucuronidase in the reported tests—supportive of safety for that strain. This does not automatically apply to all L. brevis strains or to all patient populations.

  • Oral acid production considerations: The oral isolate L. brevis BBE‑Y52 was described as a weak acid producer compared with other bacteria, which may be favorable for oral applications; however, lactobacilli can produce acids in general, and the net effect on enamel/caries risk requires clinical confirmation (not provided here).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are provided in these abstracts. None report outcomes stratified by human genetic variants (e.g., SNPs affecting neurotransmitter pathways, immune signaling, or metabolism), and no gene–probiotic interaction analyses are described.

  • What is available instead: One abstract describes development of CRISPR-based genome editing tools for Lactobacillus including L. brevis ATCC367 (a microbial genetics/biotechnology topic). This concerns engineering the bacterium, not how human genetic variation changes response or risk.

  • Practical implication: Based on these abstracts alone, there is insufficient evidence to claim L. brevis is specifically beneficial or harmful for any particular human genetic subgroup.

References

  1. Fermented fruits and vegetables of Asia: a potential source of probiotics.
    Manas Ranjan Swain, Marimuthu Anandharaj, Ramesh Chandra Ray, Rizwana Parveen Rani (2014) - Biotechnology research international
  2. Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis.
    Goda Daugėlaitė, Kristė Užkuraitytė, Eglė Jagelavičienė, Aleksas Filipauskas (2019) - Medicina (Kaunas, Lithuania)
  3. Effect of Levilactobacillus brevis as a starter on the flavor quality of radish paocai.
    Xiru Zhang, Yaxin Li, Yaran Zhao, Hui Guan, Chengwu Jin, Hansheng Gong, Xuemei Sun, Ping Wang, Huamin Li, Wenli Liu (2023) - Food research international (Ottawa, Ont.)
  4. Gaba-producing lactobacilli boost cognitive reactivity to negative mood without improving cognitive performance: A human Double-Blind Placebo-Controlled Cross-Over study.
    Melania Casertano, Matthijs Dekker, Vincenzo Valentino, Francesca De Filippis, Vincenzo Fogliano, Danilo Ercolini (2024) - Brain, behavior, and immunity
  5. Improving the bacterial community, flavor, and safety properties of northeastern sauerkraut by inoculating autochthonous
    Jiawang Wang, Xin Liu, Jiaqi Liu, Yumeng Sui, Weihua Yu, Baohua Kong, Qian Chen (2024) - Food chemistry: X
  6. Probiotic characterization ofLactobacillus brevisKU15153 showing antimicrobial and antioxidant effect isolated from kimchi
    Hye Ji Jang, Na-Kyoung Lee, Hyun-Dong Paik (2019)
  7. Gut production of GABA by a probiotic formula: an in vitro study.
    M Casertano, C Fryganas, V Valentino, A D Troise, P Vitaglione, V Fogliano, D Ercolini (2024) - Beneficial microbes
  8. Characterization of a Lactobacillus brevis strain with potential oral probiotic properties.
    Fang Fang, Jie Xu, Qiaoyu Li, Xiaoxuan Xia, Guocheng Du (2018) - BMC microbiology
  9. Development of a RecE/T-Assisted CRISPR-Cas9 Toolbox for Lactobacillus.
    He Huang, Xin Song, Sheng Yang (2019) - Biotechnology journal
  10. Probiotic Properties and Antioxidant Activities of
    Seo Jin Yang, Kee-Tae Kim, Tae Young Kim, Hyun-Dong Paik (2020) - Foods (Basel, Switzerland)
  11. Immune-Enhancing Effect of Heat-Treated Levilactobacillus brevis KU15159 in RAW 264.7 Cells.
    Chang-Hoon Hwang, Kee-Tae Kim, Na-Kyoung Lee, Hyun-Dong Paik (2023) - Probiotics and antimicrobial proteins
  12. GABA synthesizing lactic acid bacteria and genomic analysis of
    Tushar Matta, Ruchika Bhatia, Santa Ram Joshi, Mahendra Bishnoi, Kanwaljit Chopra, Kanthi Kiran Kondepudi (2024) - 3 Biotech
  13. Pasteurized form of a potential probiotic lactobacillus brevis IBRC-M10790 exerts anti-inflammatory effects on inflammatory bowel disease in vitro.
    Ardeshir Ebrahiminejad, Abbas Akhavan Sepahi, Abbas Yadegar, Anna Meyfour (2024) - BMC complementary medicine and therapies
  14. Effect of Lactic Acid Bacteria Strains on the Growth and Aflatoxin Production Potential of
    Cleide Oliveira de Almeida Møller, Luisa Freire, Roice Eliana Rosim, Larissa Pereira Margalho, Celso Fasura Balthazar, Larissa Tuanny Franco, Anderson de Souza Sant'Ana, Carlos Humberto Corassin, Fergal Patrick Rattray, Carlos Augusto Fernandes de Oliveira (2021) - Frontiers in microbiology
  15. The effects of ultrasound on probiotic functionality: an updated review.
    Thabani Sydney Manyatsi, Amin Mousavi Khaneghah, Mohsen Gavahian (2024) - Critical reviews in food science and nutrition
  16. Effects of vaginal lactobacilli in Chlamydia trachomatis infection.
    Paola Mastromarino, Marisa Di Pietro, Giovanna Schiavoni, Chiara Nardis, Massimo Gentile, Rosa Sessa (2014) - International journal of medical microbiology : IJMM
  17. Whole-genome analysis, evaluation and regulation of in vitro and in vivo GABA production from Levilactobacillus brevis YSJ3.
    Hui Liu, Daiyao Liu, Chengcheng Zhang, Haiyue Niu, Xiaoting Xin, Huaxi Yi, Daqun Liu, Jianming Zhang (2024) - International journal of food microbiology
  18. Probiotic Characterization of
    Youjin Lee, Neagawooridwimeu Kim, Pia Werlinger, Dong-A Suh, Hanki Lee, Joo-Hyung Cho, Jinhua Cheng (2022) - Journal of medicinal food
  19. Nano selenium-enriched probiotic
    Runhang Liu, Weijiao Sun, Tianzhi Sun, Wenzhi Zhang, Yongchao Nan, Zheng Zhang, Kongrui Xiang, Hongliang Yang, Fang Wang, Junwei Ge (2023) - Frontiers in immunology
  20. Submerged fermentation with
    Chih-Yu Chen, Chi-Yao Hu, Yi-Hui Chen, Ya-Ting Li, Ying-Chien Chung (2022) - Heliyon


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!